FDA Authorizes Two Vial Presentations For Moderna's COVID-19 Vaccine

The FDA approved new vials from Moderna Inc (NASDAQ: MRNA) that can contain up to 15 doses each, compared with the designed to hold ten doses.
Additionally, regulators said providers could safely extract up to 11 doses from the original 10-dose vials.
The U.S. Emergency Use Authorization label allows for vaccine vials to remain at room temperature conditions for a longer period (total of 24 hours from the previous 12 hours).
The dosing updates should help bolster the U.S. supplies and speed vaccinations as the U.S. nears 100 million inoculations against COVID-19. President Joe Biden has vowed to provide enough shots to vaccinate all U.S. adults by late May.
Moderna said it plans to begin shipping the new 15-dose vials in the coming weeks.
Price Action: MRNA shares are trading 2.3% higher at $134 in the premarket session on the last check Monday.